Proteon Therapeutics, Inc. is a developer of pharmaceuticals with offices in Waltham, Massachusetts and Kansas City, Missouri.

Proteon was founded by Dr. F. Nicholas Franano based on technology created at Johns Hopkins University.

[1] The company is led by Timothy Noyes, CEO; Steven Burke, CMO; George Eldridge, CFO; and Scott Toner, director of marketing.

[2] On March 5, 2009, the company announced that it had raised $32 million from its existing investors plus MPM Capital and Vectis Life Sciences.

In December 2016, they announced that the phase III trial of PRT-201 hadn't reached its primary endpoint, causing Proteon's stock price to drop more than 75%.